Polynucleotides
Polynucleotides for pattern hair loss: what does the evidence show?
A small uncontrolled study reported increased hair density and diameter after scalp polynucleotide injections, but diagnosis and established treatment options still come first.
Hair loss needs a diagnosis before a cosmetic procedure
Pattern hair loss develops gradually and usually follows a recognisable distribution, but thinning is not always caused by the same condition. Iron deficiency, thyroid disease, illness, rapid weight loss, medication, hormonal change, scalp inflammation and autoimmune or scarring disorders may produce shedding or loss that needs different assessment and treatment.
The NHS advises seeing a GP to understand the cause before approaching a commercial hair clinic. Sudden loss, smooth patches, scalp pain, marked redness, scale, pustules or loss of eyebrow hair particularly warrant medical review. Injecting the scalp without a clear diagnosis could delay appropriate investigation or treatment.
What did the 2025 polynucleotide study involve?
A prospective study followed 28 people diagnosed with androgenetic, or pattern, hair loss. Participants received four sessions of one specific polynucleotide formulation at four-week intervals. Researchers used dermoscopic measurements to assess hair diameter and density and also collected ratings from patients and dermatologists.
Average hair diameter and total density increased during follow-up. Dermatologists judged the condition to be stabilised in 60.7% of cases, while 82.1% of participants rated themselves as improved. No serious side effects were reported. These results are encouraging enough to justify better trials, but they do not establish a standard treatment or predict an individual outcome.
Why the study cannot prove effectiveness
There was no untreated, placebo or established-treatment comparison group, and only 28 participants were included. Everyone knew that injections had been given. Natural fluctuation, concurrent hair care, expectations, measurement variation and regression towards the average therefore cannot be separated confidently from the effect of the product.
The study tested one formulation and one four-session schedule. Its findings cannot be transferred automatically to every product described as a polynucleotide, and they do not show whether benefits persist, whether maintenance is needed or how treatment compares with established options. The sample was also too small to identify uncommon adverse effects.
Measured density is not the same as a guaranteed visible result
A statistically significant change in counted hairs or shaft diameter may still look subtle in photographs or daily life. Baseline density, duration of loss, follicle miniaturisation, age and the underlying diagnosis can affect what is achievable. Areas where follicles have been permanently destroyed, including some scarring alopecias, should not be expected to regrow from a skin-quality injectable.
Consultation should document the pattern and timing of loss, scalp findings, family history, medicines, recent illness, diet and relevant symptoms. Appropriate examination or blood tests may be needed. Evidence-based medical treatments, watchful waiting, camouflage, hair transplantation or psychological support may be more suitable, alone or as part of a wider plan.
Downtime and possible adverse effects
Multiple scalp injections can cause stinging, tenderness, redness, swelling, itching, pinpoint bleeding, small raised points or bruising. Headache or temporary sensitivity may affect comfort after treatment. The absence of serious events in 28 people does not mean that complications cannot occur, and a treatment should not be described as risk-free.
Increasing pain, spreading redness or heat, discharge, fever, marked swelling, a persistent rash or worsening scalp symptoms needs prompt assessment. Sterile technique, correct product handling, clear aftercare and access to clinical follow-up are essential. An active scalp infection or inflammatory flare may mean postponing injections.
Suitability and expectations must be individual
Medical conditions, medicines—including those affecting bleeding—pregnancy or breastfeeding, allergies, previous reactions and other planned scalp treatments must be reviewed. Product source and ingredients matter, including fish allergy where relevant. Combining procedures should not be assumed to improve results and can make adverse reactions harder to interpret.
Current evidence supports describing scalp polynucleotides as an emerging option with uncertainty, not a proven replacement for diagnosis or established care. A consultation should explain the limited evidence, alternatives, likely course, total treatment burden, downtime, cost and review plan. Choosing not to proceed is appropriate when the diagnosis is unclear or the expected benefit is too uncertain.